Vincendeau S, Jiang S, Varghese D, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Scailteux LM, Hussain A. Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends. Clin Onco. 2022 Dec 2;6(15):1-9.

BACKGROUND: This study describes the real-world frequency, management and resource use of adverse events (AEs) of special interest in non-metastatic castration-resistant prostate cancer (nmCRPC) patients receiving androgen receptor axis targeting agents (ARATs), in France.

METHODS: This was a retrospective chart review (January 1 to December 31, 2018).

RESULTS: Of 270 patients, 59.3% had ≥1 AE. with fatigue/asthenia and hot flush most commonly reported. Of the cohort experiencing at least 1 AE, 18.5% received treatment for their AEs, 10.6% discontinued therapy, 4.2% had a hospitalization, and 3.2% had dose reductions.

CONCLUSION: More than half of nmCRPC patients treated with the ARATs, bicalutamide, abiraterone, apalutamide, or enzalutamide experienced AEs and a substantial proportion required management and incurred additional healthcare resource use.

Share on: